Non-Current Assets
Deferred Tax Assets
Bristol-Myers Squibb Deferred Tax Assets increased by 141.1% to $161.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 96.0%, from $4.00B to $161.00M. Over 5 years (FY 2020 to FY 2025), Deferred Tax Assets shows a downward trend with a -19.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryRisk
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase may indicate future tax advantages or losses that can be used to offset future taxable income.
Detailed definition
These are future tax benefits that arise from temporary differences between the book value of assets and liabilities and...
Peer comparison
Standard accounting item influenced by global tax strategies and R&D tax credit utilization.
Metric ID:
deferred_tax_assetsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $650.00M | $684.00M | $1.44B | $1.42B | $1.34B | $1.33B | $1.34B | $1.32B | $1.57B | $1.51B | $2.77B | $2.72B | $3.32B | $3.61B | $4.24B | $4.00B | $4.65B | $4.96B | -$392.00M | $161.00M |
| QoQ Change | — | +5.2% | +110.4% | -1.5% | -5.7% | -0.6% | +1.1% | -2.0% | +19.4% | -3.7% | +82.8% | -1.6% | +22.0% | +8.6% | +17.4% | -5.6% | +16.3% | +6.8% | -107.9% | +141.1% |
| YoY Change | — | — | — | — | +105.7% | +94.3% | -6.6% | -7.1% | +17.6% | +13.9% | +106.0% | +106.8% | +111.4% | +138.4% | +53.0% | +46.8% | +39.8% | +37.5% | -109.3% | -96.0% |
Range-$392.00M – $4.96B
CAGR-25.5%
Avg YoY Growth+40.8%
Median YoY Growth+43.3%
Deferred Tax Assets at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's deferred tax assets?
- Bristol-Myers Squibb (BMY) reported deferred tax assets of $161.00M in Q1 2026.
- How has Bristol-Myers Squibb's deferred tax assets changed year-over-year?
- Bristol-Myers Squibb's deferred tax assets decreased by 96.0% year-over-year, from $4.00B to $161.00M.
- What is the long-term trend for Bristol-Myers Squibb's deferred tax assets?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's deferred tax assets has grown at a -19.5% compound annual growth rate (CAGR), from $1.16B to -$392.00M.
- What does deferred tax assets mean?
- Future tax savings the company expects to realize based on past financial events.